Archive for February 2024
Commentary: The small-molecule ‘penalty’ is a threat to Mass. biotech sector
The Inflation Reduction Act inadvertently introduced a change in drug-development incentives that could result in distorted decisions about which treatments get developed. Read More
Read MoreFoghorn gets $300M plus investment from Lilly under cancer drug partnership
Foghorn Therapeutics saw its stock price soar on Thursday following the news that its collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, was bearing fruit. Read More
Read MoreFoghorn’s shares rise after Lilly chooses cancer drug for development
Foghorn Therapeutics saw its stock price soar on Thursday following the news that its collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, was bearing fruit. Read More
Read MoreIRS seeks information from small businesses that received ERC — and offers a way out
The new batch of letters shows how the agency is working every angle to combat fraud in the lucrative tax-credit program. Read More
Read MoreBoston-based sports apparel brand signs licensing deal with NASCAR
The deal, announced this week, includes ‘47 headwear and apparel for NASCAR team properties, including NASCAR-owned tracks and teams. Read More
Read MoreStartups to Watch: 35 companies poised for growth in the coming years
American Inno has unveiled its Startups to Watch for 2024 featuring 35 startups you should have on your radar this year. Read More
Read MoreVertex co-founder Josh Boger joins Boston biotech working on dementia drug
Boger told the Business Journal that this Boston biotech offers “the best hope for a meaningful intervention in dementia of any kind.” Read More
Read MoreCitizens aims to strengthen private banking business with new hires
Citizens Bank has bolstered its growth in the wealth management and private banking business with two new executive hires, including a former First Republic executive. Read More
Read MoreAndrew Dreyfus, former Blue Cross CEO, joins Octave board of directors
Andrew Dreyfus was the CEO of BCBSMA for 12 years before stepping down at the end of 2022. He is now on the Octave board of directors. Read More
Read MoreFidelity’s revenue growth accelerates in 2023
Boston-based Fidelity Investments increased its revenue much faster last year than in 2022, hitting a record high. Read More
Read More